Take our survey

We value your opinion. To improve your experience on emend.com, we are conducting research to better understand the needs of our visitors.

Please take a few moments to complete a short 5-question survey.

Please be assured that this survey is for research purposes only and that your privacy will be respected. Your responses will remain strictly confidential.

Any data collected in this survey will be handled in accordance with the privacy policy of Vovici, who is administering this survey on behalf of Merck.

Your responses to this survey will be kept strictly confidential and WILL NOT be used to contact you or sell you products or information.

This survey is sponsored by Merck.

Take now Take later No thanks
EMEND (aprepitant) Dosing Information

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck

Day 1 flexibility: I.V. or P.O.

In combination with other antiemetics, EMEND provides 5 days of protection in 3 daily doses.

Realize the full benefit of EMEND.

For patients at risk of CINV due to HEC or MEC, EMEND always should be taken on Days 1, 2, and 3 of chemotherapy treatment. When using EMEND for Injection, remember to prescribe the oral regimen of EMEND (Bifold Pack).

More information »

Vial, pack, and capsules not shown at actual size.

  • EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 receptor antagonist. The recommended dosage includes EMEND (125 mg) on Day 1 followed by EMEND (80 mg) once daily on Days 2 and 3. EMEND for Injection (115 mg) may be substituted for EMEND 30 minutes before chemotherapy, on Day 1 only, as an infusion administered over 15 minutes.
  • EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated for prevention of:
    • Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
    • Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

EMEND is part of an antiemetic regimen including:

For patients treated with highly emetogenic chemotherapy
Day 1/Prechemotherapy Day 2 Day 3 Day 4
EMEND 125 mg P.O.
or
EMEND for Injection
115 mg I.V.		 EMEND 80 mg P.O. EMEND 80 mg P.O. –
5-HT3 receptor antagonist – – –
Corticosteroid Corticosteroid Corticosteroid Corticosteroid
For patients treated with moderately emetogenic chemotherapy
Day 1/Prechemotherapy Day 2 Day 3
EMEND 125 mg P.O.
or
EMEND for Injection
115 mg I.V.		 EMEND 80 mg P.O. EMEND 80 mg P.O.
5-HT3 receptor antagonist – –
Corticosteroid – –

In clinical trials, EMEND was given with ondansetron and dexamethasone.

Consider EMEND to help prevent CINV beginning with the first cycle of chemotherapy

CINV = chemotherapy-induced nausea and vomiting.
HEC = highly emetogenic chemotherapy.
MEC = moderately emetogenic chemotherapy.

Selected Important Risk Information

Caution: EMEND for Injection should not be mixed or reconstituted with solutions for which physical and chemical compatibility have not been established. EMEND for Injection is incompatible with any solutions containing divalent cations (eg, Ca2+, Mg2+), including Lactated Ringer's Solution and Hartmann's Solution.

The most frequent clinical adverse events reported in patients receiving EMEND for Injection were infusion site pain (7.6%), headache (3.0%), and infusion site induration (1.5%).

There have been isolated reports of immediate hypersensitivity reactions including flushing, erythema, and dyspnea during infusion of fosaprepitant. These reactions have generally receded when the infusion was stopped and appropriate therapy was provided. It is not recommended to reinitiate the infusion in patients who have these reactions.

Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.

For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.

20906183(6)-11/09-EME